AI
Saturday, July 24, 2021 2:34:41 PM
The graph clearly shows virtually all subjects taking Anavex 2-73 above those taking the standard of care (donepezil and/or memantine).
Effect size at week 57
Daily treatment with ANAVEX2-73 for 57 weeks for the entire Phase 2a cohort showed effect sizes of 0.57 and 0.18 for change in MMSE and change in ADCS-ADL, respectively, compared to standard of care (Table 3). When patients carrying SIGMAR1 p.Gln2Pro and COMT p.Leu146fs variants and low baseline MMSE score (9 out of 21 patients) were excluded, effect sizes increased to 1.05 and 0.93 for MMSE and ADCS-ADL, respectively (Table 3). These values are considered "large" according to Cohen's d guidelines. 51
The current standard of care for treating Alzheimer's disease is Donepezil and/or memantine. Better than placebo. The dark black line and dashed.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167374/
http://www.anavex.com/wp-content/uploads/2021/07/Anavex-Presentation-July-2021.pdf
GOD bless,
Effect size at week 57
Daily treatment with ANAVEX2-73 for 57 weeks for the entire Phase 2a cohort showed effect sizes of 0.57 and 0.18 for change in MMSE and change in ADCS-ADL, respectively, compared to standard of care (Table 3). When patients carrying SIGMAR1 p.Gln2Pro and COMT p.Leu146fs variants and low baseline MMSE score (9 out of 21 patients) were excluded, effect sizes increased to 1.05 and 0.93 for MMSE and ADCS-ADL, respectively (Table 3). These values are considered "large" according to Cohen's d guidelines. 51
The current standard of care for treating Alzheimer's disease is Donepezil and/or memantine. Better than placebo. The dark black line and dashed.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167374/
http://www.anavex.com/wp-content/uploads/2021/07/Anavex-Presentation-July-2021.pdf
GOD bless,
